Suzanne Rivera named new VP for research

Provost W.A. "Bud" Baeslack III announced, on November 4th, the appointment of Suzanne M. Rivera as Case Western Reserve´s new vice president for research, effective this month. Rivera, the university´s associate vice president for research since January 2011, emerged as the top choice after an extensive process involving campuswide nominations of internal university candidates. Since coming to CWRU, Rivera has distinguished herself through a commitment to collaboration and a focus on systems and processes.
Read more about her.


Research Matters

Click here to view previous editions of Research Matters and Research News and Updates.




Latest News

Research Newsletter
December 9, 2014  

Ohio Bureau of Workers Compensation (BWC)

The Ohio Occupational Safety and Health Research Program is administered by the Ohio Bureau of Worker’ Compensation (BWC). The program is a competitive research program with an emphasis on maximizing the impact that research efforts in the areas of occupational safety and health have on the overall safety, health, productivity and competitiveness of Ohio's workforce.

For more information and guidelines, visit the Program’s website.

 
New Facilities and Administrative (F&A) Rate for Use in Proposals

Negotiations with the Department of Health and Human Services (DHHS) regarding the University’s F&A rates have concluded. DHHS has approved a (3) three year F&A rate of 58.5% for CWRU, which is a 1.5 percentage point change from our previous rate of 57%. This rate will be effective through June 2016.

The new F&A rate should be used when preparing proposal budgets for awards with an anticipated start date of July 1, 2013 or after.

Read the full notice of this change at: https://ora.ra.cwru.edu/research/docs/2012.10.08_Facilities_and_Administrative_rate.pdf.

 

Foundation Fighting Blindness and Harrington Discovery Institute

Foundation Fighting Blindness and Harrington Discovery Institute have partnered to form, the The National Center for Excellence in Fighting Blindness, a Gund-Harrington initiative. This initiative is focused on accelerating the translation of research findings in inherited retinal degenerative diseases (IRD) with the ultimate goal of developing new therapies to improve and/or restore vision.

• This Initiative seeks to award Gund-Harrington Scholar Awards that recognize innovators throughout the USA whose research has the potential to advance standards of care.
• There will be an average of three awards per year, which will be restricted to researchers working at institutions within the USA. Applications from outside the USA are not accepted.
• The Gund-Harrington Scholar Award provides funding for translational drug development and cell therapy along with non-financial project support to help bridge the gap between laboratory-based research and the clinic.
• Funding up to a total of $900,000 over three years and non-financial support will be provided by the The National Center for Excellence in Fighting Blindness. The non-financial support, provided by a team of pharmaceutical experts, will include project management and experienced industry advice in all aspects of drug development, encompassing chemistry, formulation, toxicology, regulatory, intellectual property and business development.
• Awards will be made to physician-scientists, or scientists with a research team that includes significant involvement of a physician with clinical expertise in the IRD.
• Selected projects must demonstrate a reasonable expectation that they can develop a lead product with strong potential for clinical and commercial application by the end of the three year funding period.
Multi-disciplinary investigators outside the field of retinal disease are particularly encouraged to apply.

Applicants interested in the Gund-Harrington Scholar Awards must apply through Foundation Fighting Blindness.

For more information about Foundation Fighting Blindness visit the Fighting Blindness website.

 
New Policy from NIH to Balance Sex in Cell and Animal Studies

NIH announced last week a new policy requiring "a balance of male and female cells and animals in preclinical studies in all future applications." In this week's Nature, Janine Clayton and Francis Collins write, "The over-reliance on male animals and cells in preclinical research obscures key sex differences that could guide clinical studies. And it might be harmful: women experience higher rates of adverse drug reactions than men do. Furthermore, inadequate inclusion of female cells and animals in experiments and inadequate analysis of data by sex may well contribute to the troubling rise of irreproducibility in preclinical biomedical research."

Read more at: http://ow.ly/wSqy6.

 
eRA Commons Usernames for Graduate and Undergraduate Students

Beginning next month, any students working for more than a calendar month on an NIH grant must have an eRA Commons ID. While this notice came out last year, enforcement, including rejection of progress reports, will begin in October 2014.

Read more at: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-13-097.html.

 

If you have news or information that you wish to have included in this update, please send it via e-mail to Tracy Wilson-Holden at tracy.wilson-holden@case.edu no later than 5 pm on the Monday of the week that the update is to be distributed. If you know of individuals who may be interested in receiving this update, please forward this e-mail to them. To subscribe or unsubscribe to Case Research News, email your request to Tora Williams at tora.williams@case.edu.

Please note: At the time of this transmission, all links functioned. However, Case Research News cannot guarantee that the information will not move or be deleted.